Qsymia's US approval set to fatten revenues at Taiwan's ScinoPharm
This article was originally published in Scrip
Executive Summary
The recent US FDA approval of Vivus' anti-obesity drug Qsymia is having knock-on effects half a world away in Asia, where one of the US firm's key active pharmaceutical ingredient (API) suppliers is girding itself to meet expected demand.